Bernstein Upgrades Biogen (BIIB) to Outperform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Bernstein Upgrades Biogen (BIIB) to Outperform

Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion

July 24, 2015 6:50 AM EDT

TECFIDERA® now the most prescribed oral MS therapy globally

Sites initiated for aducanumab Phase 3 studies for Alzheimers disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2015 results, including revenues of $2.6 billion, a 7% increase compared to the second quarter of 2014. Non-GAAP diluted earnings per share (EPS) for the second quarter of 2015 were $4.22, an increase of 21% over the second quarter of 2014. Non-GAAP net income attributable to Biogen for the second quarter of 2015 was $995 million, an increase of 20% over the second... More